|PO Box 55932 , Boston, MA 02205-5932|
|Fund Manager||Andrew Acker|
|Manager Tenure||12 Years 2 Months|
Janus Henderson Global Life Sciences Fund seeks long-term growth of capital. The Fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio manager believes have a life science orientation. In the Fund s pursuit of companies with a life science orientation, the Fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the life sciences sector, which may include companies in the following industry groups: pharmaceutical; biotechnology; health care services; and medical devices. Generally speaking, the life sciences relate to maintaining or improving quality of life. So, for example, companies with a life science orientation include companies engaged in research, development, production, or distribution of products or services related to health and personal care, medicine, or pharmaceuticals. The Fund implements its investment policies by investing primarily in equity securities of U.S. and foreign companies selected for their growth potential. The Fund normally invests in issuers from several different countries, which may include the United States. The Fund may, under unusual circumstances, invest in a single country. The Fund may have exposure to emerging markets. The Fund may invest in shares of companies through initial public offerings. The portfolio manager applies a bottom up approach in choosing investments. In other words, the portfolio manager looks at companies one at a time to determine if a company is an attractive investment opportunity and if it is consistent with the Fund s investment policies. The Fund may lend portfolio securities on a short-term or long-term basis, in an amount equal to up to one-third of its total assets as determined at the time of the loan origination.
|Asset Type||% Of Allocation|
|Total Net Assets||28.94 M|
|Criteria||3 Years||5 Years||10 Years|
|Minimum Initial IRA||$500|
|Timeframe||Average Annual Current Performance Monthly As Of 08/31/2021||Average Annual Current Performance Quarterly As Of 06/30/2021||Avg Annual Current Performance Monthly As Of 08/31/2021||Avg Annual Current Performance Quarterly As Of 06/30/2021|
|Life Of Fund||
|Symbol||Company Name||% Of Assets|
|UNH||UNITEDHEALTH GROUP INC||3.97%|
|ROG||ROCHE HOLDING AG||2.91%|
|MRK||MERCK & CO||2.75%|
|NVS||NOVARTIS AG ADR||2.58%|
|BSX||BOSTON SCIENTIFIC CORP||2.45%|
|TMO||THERMO FISHER SCIENTIFIC INC||2.28%|
Join the Action Alerts PLUS Community today!
Micron topped analysts' fourth quarter expectations but provided tepid outlook for the first quarter.
Wolfe Research upgraded Chewy to outperform, saying a drop in net new customer additions should reverse in fiscal 2022.
Ahead of third-quarter earnings season, James 'Rev Shark' Deporre has some thoughts on what investors should be thinking about.
Gogo, Huntsman, Thor Industries, United Natural Foods and Sonoma Pharmaceuticals are five top stock gainers for Tuesday.
Stocks end sharply lower Tuesday as Wall Street contends with rolling blackouts in China, record high energy prices in Europe and gas line-ups in Britain.
Aurora Cannabis had a tough quarter, but Cowen analysts still expect strong growth margins in 2022.